157 related articles for article (PubMed ID: 34667669)
1. Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy.
Mandal S; Ray B; Baniya Sharma S; Poulose J; Kasireddy V
Cureus; 2021 Sep; 13(9):e17992. PubMed ID: 34667669
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.
Gonugunta AS; von Itzstein MS; Gerber DE
J Med Case Rep; 2022 Jul; 16(1):289. PubMed ID: 35871685
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Fricke J; Mambetsariev I; Pharaon R; Subbiah S; Rajurkar S; Salgia R
Medicine (Baltimore); 2020 Nov; 99(46):e22323. PubMed ID: 33181636
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
Frelaut M; du Rusquec P; de Moura A; Le Tourneau C; Borcoman E
BioDrugs; 2020 Aug; 34(4):463-476. PubMed ID: 32394415
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
Zhou L; Zhang M; Li R; Xue J; Lu Y
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to immunotherapy characterized by bloody pleural effusion and biomarker exploration: a report of 2 cases.
Zeng X; Zhang Y; Zhang Y; Lei Y; Gu K
Ann Palliat Med; 2022 Feb; 11(2):843-849. PubMed ID: 35249354
[TBL] [Abstract][Full Text] [Related]
7. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Kang DH; Chung C; Sun P; Lee DH; Lee SI; Park D; Koh JS; Kim Y; Yi HS; Lee JE
Cancer Immunol Immunother; 2022 Mar; 71(3):579-588. PubMed ID: 34278517
[TBL] [Abstract][Full Text] [Related]
8. Hyperprogression under Immunotherapy.
Frelaut M; Le Tourneau C; Borcoman E
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151303
[TBL] [Abstract][Full Text] [Related]
9. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression and hyperprogression after checkpoint blockade.
Wang Q; Gao J; Wu X
Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
[TBL] [Abstract][Full Text] [Related]
11. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
12. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.
Ji Z; Peng Z; Gong J; Zhang X; Li J; Lu M; Lu Z; Shen L
BMC Cancer; 2019 Jul; 19(1):705. PubMed ID: 31315610
[TBL] [Abstract][Full Text] [Related]
14. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma.
Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
Jpn J Clin Oncol; 2019 May; 49(5):473-476. PubMed ID: 30920617
[TBL] [Abstract][Full Text] [Related]
16. Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature.
Kazemi NY; Langstraat C; John Weroha S
Gynecol Oncol Rep; 2022 Feb; 39():100923. PubMed ID: 35111894
[TBL] [Abstract][Full Text] [Related]
17. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
[TBL] [Abstract][Full Text] [Related]
18. Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics.
Singla R; Gupta A; Batra U; Chaturvedi A; Rao A; Jajodia A
Indian J Radiol Imaging; 2021 Apr; 31(2):345-349. PubMed ID: 34556917
[No Abstract] [Full Text] [Related]
19. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
20. Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.
Doumas S; Foukas PG; Economopoulou P; Kotsantis I; Psyrri A
Oral Oncol; 2020 Jan; 100():104477. PubMed ID: 31837533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
